

Design, synthesis, and biological evaluation of substrate competitive inhibitors of C-Terminal Binding Protein (CtBP)

Sudha Korwar^{‡,a}, Benjamin L. Morris^{‡,b}, Hardik I. Parikh^a, Robert A. Coover^a, Tyler W. Doughty^c, Ian M. Love^b, Brendan J. Hilbert^c, William E. Royer, Jr.^c, Glen E. Kellogg^a, Steven R. Grossman^{b,*}, and Keith C. Ellis^{a,*}

- a. Department of Medicinal Chemistry, School of Pharmacy; the Institute for Structural Biology, Drug Discovery and Development; and the Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, 23298, United States
- b. Division of Hematology, Oncology, & Palliative Care and Department of Human and Molecular Genetics, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, United States
- c. Department of Biochemistry and Molecular Pharmacology, and Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States

Supporting Information

Table of Contents

1. Table S1	S2
2. Figure S2	S3
3. NMR Spectra	S6


Table S1. Inhibition of recombinant CtBP by Initial Set of Designed Inhibitors from Schemes **1** and **2**.

Compound	IC₅₀ (μM)^a
MTOB (1)	300
3	116.3
4	>300
5	>300
6	>300
7	>300
8	>300
9	0.24
10	>300
11	>300
12	>300
13	>300






a. Data represents the average of two replicates.

Figure S2. Stability of 9 (A), 14g (B), and 14h (C) to hydrolysis under aqueous conditions.

A.



B.



C.

